drugset / Trial / NCT03322995
Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, phase II study in patients with resectable and borderline resectable pancreas cancer.
Timeline
- Start
- 2018-06-21
- Primary completion
- 2027-06-01
- Completion
- 2032-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | — | — |
| Subject | Irinotecan | Small molecule | — | — |
| Subject | Leucovorin | Small molecule | — | — |
| Subject | Oxaliplatin | Small molecule | — | — |
| Subject | fluorouracil | Small molecule | — | — |